Jiangsu (SH:688426)2025-04-29 08:00Financial Performance - The company's revenue for Q1 2025 reached ¥43,005,484.73, representing a 49.31% increase compared to ¥28,803,048.98 in the same period last year[2] - The net profit attributable to shareholders was -¥22,743,420.04, an improvement of 21.49% from -¥28,967,442.68 year-on-year[2] - Total operating revenue for Q1 2025 was CNY 43,005,484.73, an increase of 49.5% compared to CNY 28,803,048.98 in Q1 2024[16] - Operating profit for Q1 2025 was a loss of CNY 25,746,292.62, improved from a loss of CNY 31,194,936.08 in Q1 2024[17] - Net profit for Q1 2025 was a loss of CNY 22,864,145.10, compared to a loss of CNY 29,729,571.97 in Q1 2024, showing a 23.2% improvement[17] Cash Flow - The net cash flow from operating activities improved by 35.74%, amounting to -¥18,941,859.09, primarily due to government subsidies related to assets received during the reporting period[5] - The net cash flow from operating activities was -$18,941,859.09, compared to -$29,477,526.22 in the previous period, indicating an improvement[21] - Cash inflow from investment activities totaled $149,961,811.71, down from $296,028,946.12 year-over-year[21] - The net cash flow from investment activities was -$96,219,095.19, contrasting with a positive $227,558,712.64 in the prior period[21] - Cash inflow from financing activities was $4,000,000.00, compared to $3,058,488.36 previously[22] - The net cash flow from financing activities was -$2,797,632.23, an improvement from -$9,375,489.11 in the last period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,603,599,576.78, a decrease of 0.90% from ¥1,618,129,841.84 at the end of the previous year[3] - Current assets totaled RMB 832,720,710.75, slightly down from RMB 833,404,226.85, indicating a decrease of about 0.08%[11] - The company's total liabilities amounted to RMB 72,977,200.08, down from RMB 83,995,703.30, a decrease of about 13.1%[13] - The total liabilities increased to CNY 142,449,057.99 in Q1 2025 from CNY 131,788,713.04 in Q1 2024, reflecting an increase of 7.9%[16] - Total equity attributable to shareholders decreased to CNY 1,440,715,532.79 in Q1 2025 from CNY 1,465,785,417.74 in Q1 2024, a decline of 1.7%[16] Research and Development - Research and development expenses totaled ¥21,188,472.96, accounting for 49.27% of revenue, down from 77.43% in the previous year[2] - Research and development expenses for Q1 2025 were CNY 21,188,472.96, slightly down from CNY 22,301,183.25 in Q1 2024[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 3,939[6] - The largest shareholder, Beijing Kangwei Century Biotechnology Co., Ltd., holds 44.80% of the shares, totaling 50,400,000 shares[7] - The company has not disclosed any significant changes in shareholder relationships or actions regarding stock lending or borrowing[9] Market and Product Development - The company reported a significant increase in revenue from technology service segments, particularly in sequencing technology and gene synthesis services[5] - The company has plans for market expansion and new product development, focusing on enhancing its technology service offerings[5]